| Metric | Value |
|---|---|
| Last price | $84.57 (−8.19% on the day, 12.3M shares) |
| Off 52-wk high ($143.16, May 26) | −41% |
| 52-week range | $1.80 – $143.16 |
| YTD / Trailing 12-mo | +417% / ~+4,300% |
| Market cap (~65.4M sh) | ~$5.53B |
| Beta | 1.87 |
The parabola has broken: the 10-day crossed below the 50-day on June 16, MACD has been negative since May 27, and shares have lost roughly a fifth of their value in a month after a May 22 upper-Bollinger blow-off. June traded a high of $123.20 and a low of $76.00. $76 is the level that matters — a close below opens the gap toward the low-$60s. None of this is unusual for AXTI, which routinely swings 15–25% in a day; respect the volatility in either direction.
AXT (through its Beijing subsidiary Tongmei) makes indium phosphide (InP), gallium arsenide (GaAs) and germanium substrates. The thesis in one line: as AI clusters scale out, interconnects move from copper to optics at 800G→1.6T, and InP is the only substrate that lattice-matches the InGaAs/InGaAsP layers that emit and detect light at the 1310/1550nm telecom wavelengths. Silicon can't emit light efficiently; GaAs/850nm VCSELs die out under ~50m. For mid/long-reach data-center links — and the coming co-packaged-optics (CPO) wave — InP is effectively mandatory.
The moat is the vertical integration, not the wafer slicing. AXT controls roughly four layers of the chain under one roof: (1) raw-material refining — gallium/indium/arsenic to 6N–8N purity through its ~10 China JVs, plus its own high-purity indium via JinMei; (2) pBN crucibles; (3) ingot growth; (4) substrate processing. Western device makers like Coherent are trying to integrate up into substrates but, as of now, are not at the feedstock/refinery/processing level. That depth — combined with the fact that only a handful of firms mass-produce InP substrate at scale — is what makes AXT a genuine chokepoint rather than a swappable supplier.
| Item | Q1'26 | Q4'25 | Q1'25 |
|---|---|---|---|
| Revenue | $26.9M | $23.0M | $19.4M |
| InP revenue | $13.6M (>50%) | $8.0M | $3.8M |
| Non-GAAP gross margin | 29.9% | 21.5% | −6.1% |
| GAAP EPS | −$0.03 | −$0.08 | −$0.20 |
The story is margins: a 36-point gross-margin swing in a year as InP (structurally higher margin) crossed 50% of mix and grew 70% QoQ. Backlog crossed $100M (from ~$60M). Geographic mix: Asia-Pac 78%, Europe 21%, North America 1% — that 1% is the tell on the blocked U.S. export lane.
Q2 guidance: revenue ≥ $34M, record InP $17M+, non-GAAP GM > 30%, GAAP EPS +$0.05 to $0.07 — the first profitable quarter, GAAP and non-GAAP, in company history. CFO Gary Fischer flagged the entire guide as contingent on China export permits, calling them "the most significant single factor to our growth in Q2 and beyond." On June 17, Tongmei disclosed its first publicly named long-term supply agreement — RMB 173M (~$25.4M) of InP to Nanjing Casela for 2027 delivery — the first hard evidence the $100M backlog is converting to contracts.
"InP" is not one market. There are two, and AXT sells into the smaller one:
| Layer | Size | Who captures it |
|---|---|---|
| Bulk InP substrate wafers (AXT's product) | ~$198M (2025) → $221M (2026) → $386M (2031), ~11.7% CAGR (Mordor). Technavio: +$244M 2026–30 @ ~19.8%. | Sumitomo, AXT, JX Nippon, Freiberger, Coherent (in-house) |
| Broader InP device / PIC market | ~$3B (2022) → ~$6.4B (2028), ~13.5% CAGR (Yole) | Lumentum, Coherent, module makers |
| AI optical transceiver market (context) | ~$16.5B (2025) → ~$26B (2026), +58% (TrendForce) | Transceiver/system vendors |
The shortage and the pricing power are real. 2025 global InP wafer demand ran ~2M wafers against ~600–700K of capacity — a ~70% gap; lead-supplier order books are full through 2026; AXT has pushed price hikes of ~70% to some customers. And here is the key point I want to be precise about: the InP substrate is only ~2% of an optical module's bill of materials. That is not a weakness — it is the source of pricing power. A component that is irreplaceable and a trivial share of system cost is the textbook set-up for a supplier to raise prices hard while customers sign long-term agreements (the Casela LTSA) for security rather than haggle. Think "mini-SanDisk shortage" economics. As long as the shortage persists, AXT holds real leverage.
What keeps me disciplined on price is the math, not the moat. At ~$5.53B, AXTI trades ~70× trailing FY25 sales ($88.3M) and ~40× the Q2 run-rate ($34M ×4 = $136M). AXT's own 2027 capacity target ($65–70M/qtr ≈ $260–280M annualized) would, by itself, be larger than the entire current bulk-substrate market — hitting it requires the market to roughly double and AXT to hold/grow ~25–35% share against Sumitomo, JX, Coherent's in-house lines, Freiberger and subsidized Chinese entrants, and permits to clear every quarter. Even a generous 2028 case ($300M revenue at a 20% net margin) is ~$60M of net income — still ~90× earnings at today's cap. The chokepoint is real; the price already pays for the chokepoint working perfectly for years.
I stress-tested this against the most influential AXTI bull: the anonymous AI/semi supply-chain analyst Serenity (~127K followers), who called AXTI near ~$12 and frames it as "the Strait of AXTI" — a Strait-of-Hormuz-style chokepoint where, if InP substrate fails, the photonics buildout fails. His best points sharpened this analysis:
But the bull case is narrower than it sounds, on three counts:
Reconciliation: the bull and I disagree less than it appears. Read carefully, even the most bullish voice on the planet says "fairly valued, hold through 25% drawdowns, payoff is 2027–28." That is fully consistent with "don't chase 40× sales at $84; accumulate the franchise on weakness." We differ only on method — he white-knuckles the volatility as a multi-year hold; I'd rather pay up at $55–65 with defined risk. Neither view says chase it here.
(a) Valuation already pays for perfection — ~40× forward sales; the 2027 capacity target exceeds today's whole substrate TAM. From here, any quarter below a ~40%+ growth trajectory forces violent multiple compression.
(b) Insiders are selling; dilution runway just doubled — ~$29.2M of insider sales in three months with zero buys (Lead Director Jesse Chen repeatedly June 1–17 at $86–$115; CEO Morris Young into $112–113). On June 4 shareholders raised authorized shares from 70M to 120M — runway for ~85% more dilution on top of April's $632.5M raise at $64.25. Management treats the stock as a capex-funding currency. (Caveat: post-4,000% diversification and 10b5-1 selling is partly mechanical — a yellow flag, not a red one.)
(c) The China export-permit binary is unhedgeable — all manufacturing is in China; exports of InP/GaAs/Ge need MOFCOM permits, which already capped Q4'25. Partial offset: China-domestic InP demand (no permit needed) more than doubled QoQ and is the real natural hedge, and MOFCOM has begun requesting documentation on U.S.-bound applications (encouraging, not approved). Tongmei's STAR Market IPO has sat in CSRC review since 2022.
Nominally, consensus sits far below the tape: MarketBeat consensus ~$43.80; average ~$41–42; Wedbush (Matt Bryson) the most constructive mainstream voice at Outperform ~$28; the single highest target (~$93) is roughly where the stock already trades. But in this AI bull market, "trades above consensus target" has been a worthless — even dangerous — bear signal. Micron (MU) ran from analyst targets of ~$300 (Jan) to $480 → $700 → $1,000 → $1,500 (Deutsche Bank, June 17) → $1,625 (UBS) while the stock blew through every one, closing June 18 at $1,134 — still above the ~$930 Street mean. SanDisk (SNDK) is starker: ~+692% YTD (~50-fold in a year), targets serially chased ~$1,200 (April) → $2,025 (Citi) → $2,100 (BofA) → $2,900 (Cantor), closing June 18 at $2,185 (+11.5% on the day). In both, analysts were a lagging indicator, re-rating upward as real earnings caught up. So I am explicitly retiring "you're paying ~2× the average target" as a reason to be bearish on AXTI.
The honest question is whether a stock above its average target is a momentum overshoot or a rerating analysts haven't caught up to yet. What made MU/SNDK the latter was proven, exploding, near-term EARNINGS that kept the forward P/E reasonable despite the run. AXTI is earlier on that same curve: it's guiding its first few cents of profit, not a 650%-EPS supercycle, so it still trades on ~40× sales rather than a sane forward P/E. If the margin ramp + capacity doubling + permits deliver, AXTI can absolutely follow the MU/SNDK script and drag targets up behind it — a real bull path, just not yet de-risked by the numbers. (Ignore GuruFocus's $2.57 backward-looking GF Value for the same reason you'd have ignored it on SNDK at $40.)
Bull — 40%: Q2 confirms first GAAP profit, GM pushes ~32%+, more LTSAs land, and U.S. export permits clear. The chokepoint narrative re-ignites; squeeze toward $110–120. Trigger: daily close >$108 + permit/LTSA headline.
Base — 40%: Tape stays broken below the 50-DMA (~$100); stock chops $70–90 into late July as the parabola unwinds and the dilution overhang weighs. Drift toward ~$70. Trigger: continues below 50-DMA, no new permit catalyst.
Bear — 20%: A permit disappointment or a fresh secondary (now enabled by the 120M authorization) flushes to $55–65. Trigger: 8-K permit delay or offering, or daily close <$76.
DON'T CHASE THE TOP — LOW/MODERATE CONVICTION
AXTI at $84+. A real chokepoint priced for years of flawless execution at ~40× sales with a China-permit binary. I wouldn't commit new money at the very top — but this is "don't chase," not "avoid/short." Given the MU/SNDK lesson, momentum + the demand inflection can easily carry it higher before any pullback, so the discipline is patience on entry, not a bearish bet.
SHORT — NOT RECOMMENDED (the MU/SNDK widow-maker)
I'm pulling the tactical short. In this momentum regime, shorting a real-demand chokepoint with a binary permit catalyst ahead is exactly the trade that ran over MU and SNDK bears for an entire multi-bagger. Only the nimblest traders should fade a blow-off spike (e.g. a vertical move >$120) with a tight stop above the high; everyone else, leave it alone.
BUY DIPS / WATCH — long the franchise (this is the trade)
Entry zones: start a position $66–72 (the likelier dip in a momentum tape); add aggressively $55–65 (≈25–30× a now-profitable, vertically integrated InP chokepoint) if a deeper flush comes. Targets: $108, then a momentum-driven $120+ on the MU/SNDK pattern if the Q2 print and permits deliver; multi-year optionality into the 2027–28 CPO ramp. Invalidation: weekly close <$48 or a hard China-export freeze. Timeframe: 6–12 months+. Catalyst: late-July Q2 print (first GAAP profit) + any U.S. export-permit clearance. Don't hold out for a perfect $55 entry — in this regime the dip may be shallow.
On May 31 (stock ~$103) we issued: "DO NOT CHASE >$100" and a SPEC short into $110–120, target $75, invalidation close >$132. Shares pushed to ~$123 in early June, never closed above $132, and have since fallen to $84.57 — the short worked (target $75 nearly tagged at the $76 June low). The WATCH-long $55–65 zone did not trigger (low $76). The framework held; we carry it forward, now with a more accurate read of the moat.